Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced fibrotic responses in vascular smooth muscle cells

Du,Chang-Qing; Liu,Xiao-Wei; Zeng,Guang-Zhong; Jin,Hong-Feng; Tang,Li-Jiang

doi:10.3892/ijmm.2015.2166

Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced fibrotic responses in vascular smooth muscle cells

Authors:
- Chang-Qing Du
- Xiao-Wei Liu
- Guang-Zhong Zeng
- Hong-Feng Jin
- Li-Jiang Tang
View Affiliations

Affiliations: Department of Cardiology, Zhejiang Hospital, Hangzhou, Zhejiang 310013, P.R. China
Published online on: April 2, 2015 https://doi.org/10.3892/ijmm.2015.2166
Pages: 1767-1772

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Through the regulation of the RhoA/Rho kinase (ROCK) pathway, angiotensin II (Ang II)-induced fibrotic responses contribute to vascular remodeling. Farnesyl pyrophosphate synthase (FPPS) plays an important role in cardiovascular remodeling through the modulation of the above-mentioned pathway. However, the role of FPPS in Ang II-induced fibrotic responses and the related molecular mechanisms have not yet been elucidated. In the present study, vascular smooth muscle cells (VSMCs) from Sprague-Dawley (SD) rats were stimulated with Ang II. Cell proliferation was measusred usin the cell counting kit-8 (CCK-8). The levels of connective tissue growth factor (CTGF), FPPS, and those of phosphorylated and total extracellular signal-regulated kinase (ERK)1/2, p38 and c-Jun N-terminal kinase (JNK) were determined by western blot analysis. RhoA activity was determined using a pull-down assay. The results revealed that stimulation with Ang II enhanced cell proliferation, and increased the protein expression levels of FPPS and CTGF in the VSMCs. The inhibition of FPPS with ibandronate sodium attenuated the Ang II-induced increase in cell proliferation, CTGF expresison and RhoA activity; these effects were partially reversed by treatment with geranylgeraniol and were mimicked by GGTI-286. Furthermore, both SB203580 (a specific inhibitor of p38) and SP600125 (JNK1, JNK2 and JNK3 inhibitor) diminished the Ang II-induced production of CTGF; however, the inhibition of FPPS reduced the Ang II-induced activation of p38 mitogen-activated protein kinase (MAPK) and JNK. In conclusion, our data indicate that FPPS may play an important role in Ang II-induced fibrotic responses in VSMCs, and the underlying mechanisms at least partly involve the modulation of RhoA activity, and the p38 and JNK pathways.

View Figures

View References

1	Rizzoni D, Muiesan ML, Porteri E, De Ciuceis C, Boari GE, Salvetti M, Paini A and Rosei EA: Vascular remodeling, macro-and microvessels: Therapeutic implications. Blood Press. 18:242–246. 2009. View Article : Google Scholar
2	Inoue T and Node K: Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J. 73:615–621. 2009. View Article : Google Scholar : PubMed/NCBI
3	Touyz RM and Schiffrin EL: Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 52:639–672. 2000.PubMed/NCBI
4	Fan WH, Pech M and Karnovsky MJ: Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro. Eur J Cell Biol. 79:915–923. 2000. View Article : Google Scholar
5	Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M, März W, Rupp J, Pech M and Lüscher TF: Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation. 95:831–839. 1997. View Article : Google Scholar : PubMed/NCBI
6	Rupérez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J and Ruiz-Ortega M: Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation. 108:1499–1505. 2003. View Article : Google Scholar : PubMed/NCBI
7	Rupérez M, Rodrigues-Díez R, Blanco-Colio LM, Sánchez-López E, Rodríguez-Vita J, Esteban V, Carvajal G, Plaza JJ, Egido J and Ruiz-Ortega M: HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: Role of RhoA/ROCK and MAPK pathways. Hypertension. 50:377–383. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ohtsu H, Mifune M, Frank GD, Saito S, Inagami T, Kim-Mitsuyama S, Takuwa Y, Sasaki T, Rothstein JD, Suzuki H, et al: Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol. 25:1831–1836. 2005. View Article : Google Scholar : PubMed/NCBI
9	Kobayashi N, Nakano S, Mita S, Kobayashi T, Honda T, Tsubokou Y and Matsuoka H: Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp Ther. 301:459–466. 2002. View Article : Google Scholar : PubMed/NCBI
10	Roskoski R Jr: Protein prenylation: A pivotal posttranslational process. Biochem Biophys Res Commun. 303:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
11	Li L, Hu SJ, Dong HT, Kang L, Chen NY and Fang YQ: Alterations in gene expression of series key enzymes in mevalonic acid pathway detected by RNA array in spontaneously hypertensive rats. Chin J Pathophysiol. 24:54–59. 2008.
12	Ye Y, Hu SJ and Li L: Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: Involvement of the RhoA/Rho kinase pathway. FEBS Lett. 583:2997–3003. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ye Y, Mou Y, Bai B, Li L, Chen GP and Hu SJ: Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy. Int J Biochem Cell Biol. 42:2056–2064. 2010. View Article : Google Scholar : PubMed/NCBI
14	Li L, Chen GP, Yang Y, Ye Y, Yao L and Hu SJ: Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats. Biochem Pharmacol. 79:399–406. 2010. View Article : Google Scholar
15	Yang J, Mou Y, Wu T, Ye Y, Jiang JC, Zhao CZ, Zhu HH, Du CQ, Zhou L and Hu SJ: Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice. Cardiovasc Res. 97:490–499. 2013. View Article : Google Scholar
16	Du CQ, Yang L, Yang J, Han J, Hu XS, Wu T and Hu SJ: Inhibition of farnesyl pyrophosphate synthase prevents norepinephrine-induced fibrotic responses in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens Res. 37:26–34. 2014. View Article : Google Scholar
17	Owens JM, Fuller K and Chambers TJ: Osteoclast activation: Potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J Cell Physiol. 172:79–86. 1997. View Article : Google Scholar : PubMed/NCBI
18	Papapoulos SE: Ibandronate: A potent new bisphosphonate in the management of postmenopausal osteoporosis. Int J Clin Pract. 57:417–422. 2003.PubMed/NCBI
19	van Beek E, Pieterman E, Cohen L, Löwik C and Papapoulos S: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 264:108–111. 1999. View Article : Google Scholar : PubMed/NCBI
20	Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG and Oppermann U: The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA. 103:7829–7834. 2006. View Article : Google Scholar : PubMed/NCBI
21	Lefkovits J and Topol EJ: Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis. 40:141–158. 1997. View Article : Google Scholar : PubMed/NCBI
22	Kiernan TJ, Yan BP, Cruz-Gonzalez I, Cubeddu RJ, Caldera A, Kiernan GD and Gupta V: Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting. Cardiovasc Hematol Agents Med Chem. 6:116–124. 2008. View Article : Google Scholar : PubMed/NCBI
23	Ylitalo R, Oksala O, Ylä-Herttuala S and Ylitalo P: Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med. 123:769–776. 1994.PubMed/NCBI
24	Danenberg HD, Golomb G, Groothuis A, Gao J, Epstein H, Swaminathan RV, Seifert P and Edelman ER: Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation. 108:2798–2804. 2003. View Article : Google Scholar : PubMed/NCBI
25	Wu L, Zhu L, Shi WH, Yu B and Cai D: Zoledronate inhibits intimal hyperplasia in balloon-injured rat carotid artery. Eur J Vasc Endovasc Surg. 41:288–293. 2011. View Article : Google Scholar
26	Güzeloğlu M, Gül M, Reel B, Yürekli I, Aykut K and Hazan E: The effects of zoledronic acid on neointimal hyperplasia: A rabbit carotid anastomosis model. Anadolu Kardiyol Derg. 11:93–100. 2011. View Article : Google Scholar
27	Su JZ, Fukuda N, Kishioka H, Hu WY and Kanmatsuse K: Etidronate influences growth and phenotype of rat vascular smooth muscle cells. Pharmacol Res. 46:7–13. 2002. View Article : Google Scholar : PubMed/NCBI
28	Wu L, Zhu L, Shi WH, Zhang J, Ma D and Yu B: Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol. 602:124–131. 2009. View Article : Google Scholar
29	Albadawi H, Haurani MJ, Oklu R, Trubiano JP, Laub PJ, Yoo HJ and Watkins MT: Differential effect of zoledronic acid on human vascular smooth muscle cells. J Surg Res. 182:339–346. 2013. View Article : Google Scholar :
30	Van Aelst L and D’Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev. 11:2295–2322. 1997. View Article : Google Scholar : PubMed/NCBI
31	Miyata Y and Nishida E: Distantly related cousins of MAP kinase: Biochemical properties and possible physiological functions. Biochem Biophys Res Commun. 266:291–295. 1999. View Article : Google Scholar : PubMed/NCBI